PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
This study showed that mismatch-repair status predicted clinical benefit of immune checkpoint blockade with pembrolizumab. (Funded by Johns Hopkins University and others; Clinic...
Publications
View AllGenetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
These findings define a genetic basis for benefit from CTLA-4 blockade in melanoma and provide a rationale for examining exomes of patients for whom anti-CTLA-4 agents are being...
Neoadjuvant PD-1 Blockade in Resectable Lung Cancer
Neoadjuvant nivolumab was associated with few side effects, did not delay surgery, and induced a major pathological response in 45% of resected tumors. The tumor mutational burd...
Localized Oncolytic Virotherapy Overcomes Systemic Tumor Resistance to Immune Checkpoint Blockade Immunotherapy
Intratumoral treatment with an oncolytic virus results in inflammatory infiltrates in distant tumors and sensitizes the tumors to immune-mediated rejection in the setting of imm...
Institution Info
- Type
- nonprofit
- Country
- US
- Publications
- 4
- Citations
- 16,131
External Links
Identifiers
- ROR
- https://ror.org/05d8ft347